Home > HSP & HIV Protease & HSP & > Nelfinavir Mesylate

Nelfinavir Mesylate

甲磺酸奈非那韦

Nelfinavir Mesylate 是口服的人HIV-1蛋白酶抑制剂，Ki为2nM。

目录号
EY0327
EY0327
EY0327
EY0327
纯度
99.27%
99.27%
99.27%
99.27%
规格
5 mg
10 mg
25 mg
50 mg
原价
560
840
1800
2960
售价
560
840
1800
2960
库存
现货
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Nelfinavir Mesylate is a potent HIV protease inhibitor with Ki of 2 nM.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Jensen K,et al. Nelfinavir inhibits proliferation and induces DNA damage in thyroid cancer cells. Endocr Relat Cancer. 2017 Jan 30. pii: ERC-16-0568. doi: 10.1530/ERC-16-0568.
    [2] Sangenito LS,et al. Nelfinavir and lopinavir impair Trypanosoma cruzi trypomastigote infection in mammalian host cells and show anti-amastigote activity. Int J Antimicrob Agents. 2016 Dec;48(6):703-711. doi: 10.1016/j.ijantimicag.2016.09.017.

    分子式
    C33H49N3O7S2    		 分子量
    663.89    		 CAS号
    159989-65-8    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    100 mg/mL    		 Water
    <1 mg/mL    		 Ethanol
    100 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT03077451 Recurrent Kaposi Sarcoma|Skin Kaposi Sarcoma Other: Laboratory Biomarker Analysis|Drug: Nelfinavir Mesylate AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation|University of Arkansas|University of California, Los Angeles|AIDS and Cancer Specimen Resource Phase 2 2017-03-13 2017-03-13
    NCT00704600 Colorectal Cancer|Colorectal Carcinoma|Colorectal Tumors|Neoplasms, Colorectal Drug: nelfinavir Maastricht Radiation Oncology Phase 1|Phase 2 2008-09-01 2014-12-05
    NCT00246610 HIV Infection Drug: Nelfinavir mesylate, 625 mg Pfizer Phase 4 2006-03-01 2011-04-26
    NCT02080416 Non-Hodgkin Lymphoma|Hodgkin Lymphoma|Kaposi Sarcoma|Gastric Cancer|Nasopharyngeal Cancer|EBV|Castleman Disease Drug: Nelfinavir Sidney Kimmel Comprehensive Cancer Center Early Phase 1 2014-07-01 2016-06-08
    NCT01925378 Cervical Dysplasia Drug: Nelfinavir Joseph Anthony Lucci III|The University of Texas Health Science Center, Houston Phase 2 2012-07-01 2017-02-22
    NCT01164709 Leukemia|Lymphoma|Mature T-cell and Nk-cell Neoplasms|Multiple Myeloma and Plasma Cell Neoplasm Drug: bortezomib|Drug: nelfinavir mesylate Swiss Group for Clinical Cancer Research Phase 1 2010-07-01 2014-01-31
    NCT02066311 Systemic Lupus Erythematosus Drug: Nelfinavir Northwell Health|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Phase 2 2014-09-01 2017-01-17
    NCT01065844 Carcinoma, Adenoid Cystic|Head and Neck Neoplasms Drug: Nelfinavir University of Iowa|Holden Comprehensive Cancer Center Phase 2 2009-10-01 2016-10-25
    NCT01447589 Lung Cancer Drug: nelfinavir|Radiation: Radical Radiotherapy Oxford University Hospitals NHS Trust Phase 1|Phase 2 2012-02-01 2016-06-22
    NCT03050060 Metastatic Renal Cell Cancer|Recurrent Melanoma|Recurrent Non-Small Cell Lung Carcinoma|Recurrent Renal Cell Carcinoma|Stage IV Non-Small Cell Lung Cancer|Stage IV Renal Cell Cancer|Stage IV Skin Melanoma Radiation: Hypofractionated Radiation Therapy|Other: Laboratory Biomarker Analysis|Drug: Nelfinavir Mesylate|Biological: Nivolumab University of Washington|National Cancer Institute (NCI) Phase 2 2017-04-01 2017-02-08
    NCT01728779 Oligometastases Drug: Nelfinavir|Radiation: Stereotactic Body Radiation (SBRT) Sidney Kimmel Comprehensive Cancer Center Phase 2 2013-04-01 2016-06-08
    NCT01079286 Renal Cell Cancer|Cancer Drug: Nelfinavir and temsirolimus Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Phase 1 2009-06-01 2013-07-12
    NCT00791336 Carcinoma, Non-Small-Cell Lung Drug: Nelfinavir University of Iowa Phase 2 2008-08-01 2015-04-09
    NCT00002165 HIV Infections Drug: Nelfinavir mesylate Agouron Pharmaceuticals|NIH AIDS Clinical Trials Information Service null 2005-06-23
    NCT01555281 Multiple Myeloma Drug: Nelfinavir|Drug: Lenalidomide|Drug: Dexamethasone Swiss Group for Clinical Cancer Research Phase 1|Phase 2 2012-04-01 2016-12-20
    NCT02188537 Myeloma Drug: Nelfinavir|Drug: bortezomib|Drug: Dexamethasone Swiss Group for Clinical Cancer Research Phase 2 2014-12-01 2016-08-15
    NCT01086332 Pancreatic Neoplasms Drug: Nelfinavir|Drug: Gemcitabine University of Iowa|Holden Comprehensive Cancer Center Phase 1 2009-05-01 2017-02-09
    NCT01445106 Solid Tumors Drug: Nelfinavir|Drug: Nelfinavir Mesylate National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Phase 1 2006-12-11 2017-01-24
    NCT00694837 Glioblastoma Drug: nelfinavir Maastricht Radiation Oncology|Maastricht University Medical Center Phase 1 2009-03-01 2015-04-09
    NCT00002164 HIV Infections Drug: Nelfinavir mesylate Agouron Pharmaceuticals|NIH AIDS Clinical Trials Information Service Phase 1 null 2005-06-23
    NCT03077451 Recurrent Kaposi Sarcoma|Skin Kaposi Sarcoma Other: Laboratory Biomarker Analysis|Drug: Nelfinavir Mesylate AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation|University of Arkansas|University of California, Los Angeles|AIDS and Cancer Specimen Resource Phase 2 2017-03-13 2017-03-13
    NCT00704600 Colorectal Cancer|Colorectal Carcinoma|Colorectal Tumors|Neoplasms, Colorectal Drug: nelfinavir Maastricht Radiation Oncology Phase 1|Phase 2 2008-09-01 2014-12-05
    NCT00246610 HIV Infection Drug: Nelfinavir mesylate, 625 mg Pfizer Phase 4 2006-03-01 2011-04-26
    NCT02080416 Non-Hodgkin Lymphoma|Hodgkin Lymphoma|Kaposi Sarcoma|Gastric Cancer|Nasopharyngeal Cancer|EBV|Castleman Disease Drug: Nelfinavir Sidney Kimmel Comprehensive Cancer Center Early Phase 1 2014-07-01 2016-06-08
    NCT01925378 Cervical Dysplasia Drug: Nelfinavir Joseph Anthony Lucci III|The University of Texas Health Science Center, Houston Phase 2 2012-07-01 2017-02-22
    NCT01164709 Leukemia|Lymphoma|Mature T-cell and Nk-cell Neoplasms|Multiple Myeloma and Plasma Cell Neoplasm Drug: bortezomib|Drug: nelfinavir mesylate Swiss Group for Clinical Cancer Research Phase 1 2010-07-01 2014-01-31
    NCT02066311 Systemic Lupus Erythematosus Drug: Nelfinavir Northwell Health|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Phase 2 2014-09-01 2017-01-17
    NCT01065844 Carcinoma, Adenoid Cystic|Head and Neck Neoplasms Drug: Nelfinavir University of Iowa|Holden Comprehensive Cancer Center Phase 2 2009-10-01 2016-10-25
    NCT01447589 Lung Cancer Drug: nelfinavir|Radiation: Radical Radiotherapy Oxford University Hospitals NHS Trust Phase 1|Phase 2 2012-02-01 2016-06-22
    NCT03050060 Metastatic Renal Cell Cancer|Recurrent Melanoma|Recurrent Non-Small Cell Lung Carcinoma|Recurrent Renal Cell Carcinoma|Stage IV Non-Small Cell Lung Cancer|Stage IV Renal Cell Cancer|Stage IV Skin Melanoma Radiation: Hypofractionated Radiation Therapy|Other: Laboratory Biomarker Analysis|Drug: Nelfinavir Mesylate|Biological: Nivolumab University of Washington|National Cancer Institute (NCI) Phase 2 2017-04-01 2017-02-08
    NCT01728779 Oligometastases Drug: Nelfinavir|Radiation: Stereotactic Body Radiation (SBRT) Sidney Kimmel Comprehensive Cancer Center Phase 2 2013-04-01 2016-06-08
    NCT01079286 Renal Cell Cancer|Cancer Drug: Nelfinavir and temsirolimus Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Phase 1 2009-06-01 2013-07-12
    NCT00791336 Carcinoma, Non-Small-Cell Lung Drug: Nelfinavir University of Iowa Phase 2 2008-08-01 2015-04-09
    NCT00002165 HIV Infections Drug: Nelfinavir mesylate Agouron Pharmaceuticals|NIH AIDS Clinical Trials Information Service null 2005-06-23
    NCT01555281 Multiple Myeloma Drug: Nelfinavir|Drug: Lenalidomide|Drug: Dexamethasone Swiss Group for Clinical Cancer Research Phase 1|Phase 2 2012-04-01 2016-12-20
    NCT02188537 Myeloma Drug: Nelfinavir|Drug: bortezomib|Drug: Dexamethasone Swiss Group for Clinical Cancer Research Phase 2 2014-12-01 2016-08-15
    NCT01086332 Pancreatic Neoplasms Drug: Nelfinavir|Drug: Gemcitabine University of Iowa|Holden Comprehensive Cancer Center Phase 1 2009-05-01 2017-02-09
    NCT01445106 Solid Tumors Drug: Nelfinavir|Drug: Nelfinavir Mesylate National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) Phase 1 2006-12-11 2017-01-24
    NCT00694837 Glioblastoma Drug: nelfinavir Maastricht Radiation Oncology|Maastricht University Medical Center Phase 1 2009-03-01 2015-04-09
    NCT00002164 HIV Infections Drug: Nelfinavir mesylate Agouron Pharmaceuticals|NIH AIDS Clinical Trials Information Service Phase 1 null 2005-06-23

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：